# Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate

> **NCT07158398** · PHASE1 · COMPLETED · sponsor: **Deciphera Pharmaceuticals, LLC** · enrollment: 20 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Vimseltinib
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT07158398
- **Lead sponsor:** Deciphera Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-10-31
- **Primary completion:** 2025-12-08
- **Final completion:** 2025-12-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07158398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07158398, "Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07158398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*